Oxford BioDynamics Plc (AIM: OBD), the Oxford-based 3D genomics company, has published an operational update ahead of its annual results for the year ended 30 September 2026, reporting a 124% year-on-year increase in EpiSwitch PSE test volumes and full-year revenue of £1.65m. The company also confirmed its first EpiSwitch Orion agreement with a pharmaceutical partner — a biomarker discovery project in inflammatory bowel disease for Johnson & Johnson — announced on 5 November 2026. With cash of £7.4m on its balance sheet and a new chief executive in post, the update offers investors a detailed picture of commercial progress across the Group's diagnostics and discovery divisions.

Key Points

  • Oxford BioDynamics Plc (AIM: OBD)
  • Approximately 4,200 EpiSwitch PSE tests sold in FY26, a 124% increase year-on-year, with a single-month record of more than 500 tests reached in September 2026
  • FY26 revenue of £1.65m (FY25: £1.10m); cash and cash equivalents of £7.4m at 30 September 2026; audited full-year results expected mid-December 2026
  • Investors may be watching for further EpiSwitch Orion commercial agreements, PSE reimbursement progress in the US, and partner funding for EpiSwitch NST

EpiSwitch PSE Volume Growth Reaches 500-Test Monthly Milestone in September 2026

OBD's diagnostics division, which generates almost all current Group revenue, delivered approximately 4,200 EpiSwitch PSE prostate cancer detection tests in the year ended 30 September 2026 — a 124% increase on the prior year. The announcement states that more than 500 tests were ordered in a single month for the first time in September 2026, with a further record monthly total recorded in October 2026. Both the number of clinics ordering the test and those making repeat orders grew during the period. The company's US team has been reorganised to prepare for higher throughput, either in-house or through partnering, and to improve reimbursement efficiency.

Johnson & Johnson Orion Agreement Marks First Pharma Deal for OBD's 3D Genomics Discovery Platform

On 5 November 2026, OBD announced its first EpiSwitch Orion agreement with a pharmaceutical partner, a biomarker discovery project in inflammatory bowel disease with Johnson & Johnson. EpiSwitch Orion is described in the announcement as a cloud-based, AI-powered platform that predicts 3D regulatory architecture from existing genome data, linking non-coding disease variants to the genes they regulate. The platform is built on a knowledgebase of over 1.5 billion data points validated across more than 18,000 patient samples in more than 40 diseases. An early access programme is underway ahead of a full platform release planned for the Festival of Genomics & Biodata in London in January 2027.

£7.4m Cash Position Maintained Following August 2026 Fundraise as Costs Are Reviewed

Following a £9.15m equity fundraise completed in August 2026, the company held cash and cash equivalents of £7.4m at 30 September 2026, with a further £0.5m of fundraise proceeds received after that date. The announcement states that OBD is funding the cost of external contractors and new staff by reducing other expenditure, and has terminated or paused certain advisory contracts. The company expects to continue reviewing costs in the coming months. Richard Compton, appointed Chief Executive Officer in June 2026, previously served as Senior Vice President for Sales and Commercial Operations at Oxford Nanopore Technologies plc, bringing 25 years of commercial leadership experience to OBD.

Colorectal Cancer Study Results Shared With Multinational Partner as EpiSwitch NST Development Route Is Assessed

Results from a blinded colorectal cancer study, conducted on a small cohort of samples with a multinational healthcare partner, have been shared with that partner and the study unblinded, according to the announcement. OBD states it expects to engage with multiple potential partners before determining the preferred development route for EpiSwitch NST. Separately, efforts to secure a partner-funded evidence programme for EpiSwitch CiRT are continuing. The Board's stated intention is to partner its pipeline tests — and potentially its existing tests — with suitable third parties, a strategy that means commercial progress will in part depend on third-party decisions and timelines outside the company's direct control.